Nightingale Health
Nightingale Health is a Finnish public health technology company that uses proprietary NMR metabolomics to measure 250 biomarkers from a single blood sample, providing multi-disease risk prediction for healthcare providers, insurers, governments, biobanks, and consumers across Europe, North America, and Asia.
- Company typePublic
- Founded2013
- HeadquartersHelsinki, Finland
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What Nightingale Health does
Nightingale Health is a Finnish health technology company founded in 2013 and headquartered in Helsinki. Its core offering is a proprietary NMR (Nuclear Magnetic Resonance) metabolomics platform that measures over 250 biomarkers from a single blood sample to predict risk for multiple chronic diseases — including cardiovascular disease, Type 2 diabetes, dementia, heart failure, and cancer. The platform has been validated across more than 900 scientific publications and is supported by regulatory certifications including CE marking for its at-home IVD blood collection kit, ISO 13485, ISO/IEC 27001, and a New York State clinical laboratory permit.
The company serves four primary customer segments: healthcare providers (hospitals, clinics, laboratories), insurers (underwriting and wellness programs), governments and health systems (population screening and preventive healthcare), and medical researchers/biobanks (large-scale metabolomic studies). It also operates a direct-to-consumer channel under the Nightingale Home, Nightingale Pro, My Nightingale, and Livit by Nightingale Health brands, including an at-home fingerstick blood collection device with results delivered via mobile application. Nightingale is publicly listed on Nasdaq First North Growth Market Finland following a 2021 IPO that raised approximately EUR 110 million from institutional investors.
Nightingale generates revenue through a mix of subscription-based and per-test pricing. Consumer pricing includes a Terveystalo + Nightingale Well-being Membership at approximately EUR 120 per year and unit-priced at-home tests distributed via Yliopiston Apteekki pharmacies. Enterprise and government contracts are quote-based and span laboratory services, population screening, and biobank research collaborations. Distribution is operated through own-laboratories in Finland, the US, the UK, Japan, and Singapore, complemented by strategic channel partners including Terveystalo, Yliopiston Apteekki, 23andMe, and Formula 100 Health. The business has scaled internationally through partnerships with BioBank Japan, UK Biobank, THL Biopankki, and 23andMe, and through acquisitions of Yolife GmbH (2021), Negen Oy (2022), and My Nightingale (2024).
Nightingale Health firmographics
Firmographics- Name
- Nightingale Health
- Legal name
- Nightingale Health Oyj
- Website
- https://nightingalehealth.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Nightingale Health is a Finnish public health technology company that uses proprietary NMR metabolomics to measure 250 biomarkers from a single blood sample, providing multi-disease risk prediction for healthcare providers, insurers, governments, biobanks, and consumers across Europe, North America, and Asia.
- Ownership category
- akta.pro rank
Nightingale Health industry classification
Industry- Product category
- Preventive Blood Diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Metabolomics & Lipidomics Services (HLAGANAG)
- akta.pro secondary industries
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Nightingale Health is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices5 records
Markets served
Nightingale Health business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Healthcare Services Revenue: Revenue from providing blood analysis services to healthcare providers, insurance companies, and governments. The company offers subscription-based and per-test pricing models for its Nightingale Health Check and disease risk assessment services.
- Consumer Health Services: Direct-to-consumer revenue through wellness membership programs like the Terveystalo + Nightingale Well-being Membership at EUR 9.90/month, and Nightingale Home/Pro service models for individual health monitoring.
- Research and Biobank Services: Revenue from research collaborations with biobanks (BioBank Japan, UK Biobank, THL Biopankki) for large-scale metabolomic analysis of population samples for medical research purposes.
- Technology Licensing: Licensing of proprietary NMR metabolomics technology and disease risk prediction algorithms to healthcare partners, research institutions, and international markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Terveystalo + Nightingale Well-being Membership - subscription service combining blood analysis with wellness coaching |
| Unit Pricing | Pay-as-you-go | Nightingale Home - at-home blood testing service for consumers |
| Unit Pricing | Pay-as-you-go | Nightingale Pro - laboratory-based blood analysis with comprehensive individual blood values for healthcare providers |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels8 records
Nightingale Health product offering
Product offeringCore offering
Nightingale Health provides an advanced blood analysis platform that uses proprietary NMR (Nuclear Magnetic Resonance) metabolomics technology to measure over 250 biomarkers from a single blood sample, enabling multi-disease risk prediction (cardiovascular disease, type 2 diabetes, dementia, cancer) for healthcare providers, insurers, governments, researchers, and consumers through laboratory-based and at-home service models.
Product overview
Nightingale Health offers a unified health check platform with multiple service models and research products. The core offering consists of Nightingale Health Check and Remote Health Check, which provide multi-disease risk detection from a single blood sample using proprietary NMR metabolomics technology. For consumers, Nightingale Home enables self-collected fingerstick blood samples, while Nightingale Pro serves healthcare providers requiring detailed venous blood analysis with comprehensive blood values. The company also provides research services including venous blood analysis, dried blood analysis (Nightingale Kit), urine analysis, metabolomics, and proteomics through its research portal. Partnerships include the Terveystalo Well-being Membership combining blood analysis with lifestyle coaching. The platform has been validated in over 900 scientific publications and serves B2B and B2G customers across laboratories in the US, UK, Japan, Singapore, and Finland.
Differentiator
Problem solved
Functional benefit
Brands
- Nightingale Home: Consumer self-service model where customers take their own blood sample using a fingerstick device at home
- Nightingale Pro
Products and services
- Nightingale Health Check The company's flagship advanced health check solution providing multi-disease risk detection from a single blood sample using proprietary NMR metabolomics technology; can be scaled to entire populations at low cost; targeted at healthcare providers, insurers, and government health systems.
- Remote Health Check An at-home health check solution enabling consumers to collect blood samples remotely using a fingerstick device and receive comprehensive multi-disease risk analysis through a mobile application; targeted at individual consumers and telehealth service providers.
- Nightingale Home Consumer-facing service model where individuals self-collect fingerstick blood samples using an easy-to-use device, mail the sample to Nightingale for NMR analysis, and receive results via a mobile application including a unique health index and health metrics.
- Nightingale Pro Full-service model for healthcare professionals with venous blood draw in a laboratory setting; provides a unique health index, health metrics, and detailed individual blood values to enable healthcare providers to support patients in lifestyle and treatment decisions.
- Terveystalo + Nightingale Well-being Membership Subscription-based well-being membership combining Nightingale's blood analysis with Terveystalo's well-being programs, including digital lifestyle coaching, regular measurements, health index, and indicators such as heart age, fatty acid balance, inflammation, and cholesterol balance.
- Venous Blood Analysis Research service analyzing venous blood samples to provide comprehensive NMR-based metabolomic biomarker data for academic, biobank, and medical research applications.
- Dried Blood Analysis + Nightingale Kit Research service analyzing dried blood spot samples using the proprietary Nightingale Kit, enabling convenient sample collection and shipment for metabolomic analysis in research settings.
- Urine Analysis Research service providing NMR-based metabolomic analysis of urine samples for health research applications.
- Metabolomics NMR-based metabolomics service providing comprehensive metabolic biomarker profiling from blood samples for research applications; recognized as a gold standard 'omics service for the research community.
- Proteomics Proteomics analysis service for research applications, extending Nightingale's multi-omics capabilities beyond metabolomics.
- Nightingale Analysis Service for Medical Research Comprehensive analysis service for medical researchers utilizing Nightingale's proprietary blood analysis technology and biomarker data platform for research applications.
Quantifiable outcome
- 44% improvement in prevention of heart attacks and strokes compared to current clinical practice
- +3 more outcomes
Companies that use Nightingale Health
Customer profileNamed customers7 records
Segments6 records
Ideal customer profiles6 records
Nightingale Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Nightingale Health partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered major, core and minor.
- Formula 100 HealthmajorPartnership in preventive health embedding multi-disease risk detection across longevity programs. Partnership brings Nightingale's disease risk assessment to Formula 100's longevity programs in Switzerland and South Africa.
- UK BiobankcoreNightingale enables access to world's largest metabolomics dataset through UK Biobank collaboration. Nearly 250 metabolites measured in blood samples from 500,000 volunteers over several years. Combined with genetic, lifestyle, and medical information to enable predictive medicine at scale. Metabolite-based blood test for Type 2 diabetes risk prediction currently used in clinics in Finland and Singapore.
- 23andMemajorStrategic collaboration to pilot blood biomarker panel with cohort of 23andMe members. Pilot will evaluate utility of blood testing data in improving health risk assessments and lifestyle interventions. Offering up to 5,000 members free blood testing. Initiative toward making blood testing more accessible and integrated with genetic health services.
- Yliopiston ApteekkicoreCommercial partnership for nationwide distribution of Nightingale's at-home testing solution in Finland. At-home testing solution available through Yliopiston Apteekki's online pharmacy by end of 2021 and physical pharmacies nationwide during first half of 2022. Major milestone in commercialization of at-home testing offering.
- ReaktorminorStrategic partnership with Reaktor for accelerating international growth. Reaktor provides consulting and implementation support for Nightingale's global expansion strategy.
- TerveystalocoreStrategic partnership agreement with Finland's largest healthcare company. Terveystalo develops new wellbeing services using Nightingale's blood analysis technology. New subscription service built and offered through Terveystalo application. Terveystalo receives exclusivity as private healthcare partner in Finland. Partnership valid at least until end of 2025 with expansion possibility to Nordic and Baltic countries. Revenue sharing model for service sales.
- BioBank JapancoreLong-term collaboration with one of the world's largest disease biobanks (over 200,000 participants, 640,000+ serum samples, 270,000 DNA samples). Joint research effort to identify disease risk factors in Japanese population for personalized medicine and prevention. Pilot phase started November 2020; ongoing sample analysis in Nightingale's Japan laboratory with over 10,000 samples analyzed. First results validated Nightingale's disease risk detection models for Japanese population.
- KIHUminorPartnership with KIHU (Jyväskylä University and Olympic Research) for athlete health and performance improvement. Nightingale's blood analysis technology used to support Finnish athletes.
- THL BiopankkicoreCollaboration to analyze 40,000 blood samples from Finland's largest biobank. Project aims to accelerate implementation of personalized healthcare in Finnish healthcare. Nightingale's technology enables analysis of large biobank samples at unprecedented scale and low cost.
Scale indicators7 records
Recent moves8 records
Expansion highlights7 records
Nightingale Health competitors and assessment
Company assessmentBroad incumbents
- Guardant Health:
- Bruker Corporation: Bruker is a major manufacturer of NMR and mass spectrometry instruments, including metabolomics-capable platforms. It represents a potential supply and competitive threat: a large incumbent that could vertically integrate or partner with similar end-markets.
- Thermo Fisher Scientific: Thermo Fisher offers mass spectrometry-based metabolomics workflows, clinical diagnostic instruments, and laboratory services. It is a broad incumbent in analytical instruments and clinical diagnostics that competes for hospital, biobank, and research lab spend overlapping with Nightingale.
- Exact Sciences: Exact Sciences is a multi-biomarker diagnostics company (Cologuard, Oncotype) selling blood- and stool-based screening tests into clinical workflows. It is a broader incumbent in blood-based multi-disease screening and a comparable reference point for scaling a biomarker-based clinical platform.
- Quest Diagnostics: Quest Diagnostics is a large US clinical laboratory network offering routine and specialty blood testing. It is a broader incumbent in medical laboratory services and a likely partner or competitor for population-scale screening deployments.
Direct peers
- Metabolon: Metabolon is the most direct competitor in metabolomics profiling, offering mass spectrometry-based biomarker analysis to research and clinical customers. Both companies compete for biobank and pharmaceutical research contracts and overlap heavily in disease risk biomarker discovery.
Emerging players
- GRAIL: GRAIL develops blood-based multi-cancer early detection tests (Galleri). It overlaps with Nightingale in using a single blood draw to detect risk for multiple diseases, and represents a high-profile emerging player in multi-disease blood screening.
- Freenome: Freenome is developing blood-based tests for early cancer detection using multi-omics approaches. It is an emerging player with a partial overlap with Nightingale in single-blood-draw, multi-disease risk detection.
- InsideTracker: InsideTracker offers consumer-facing blood-based health and wellness testing with personalized recommendations. It is an emerging player in the consumer blood testing segment where Nightingale's Remote Health Check and Terveystalo membership compete.
- Function Health: Function Health sells consumer subscription blood testing (300+ biomarkers) with a focus on prevention and longevity. It is an emerging player in the same consumer preventive health subscription category as Nightingale's Terveystalo membership and Remote Health Check.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Nightingale Health social profiles
Digital presenceNightingale Health compliance and trust
Trust signalCompliance4 records
Nightingale Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nightingale Health leadership team
Management profileNumber of profiles
Profiles6 records
Nightingale Health subsidiaries and ownership
Company hierarchySubsidiaries4 records
Nightingale Health funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nightingale Health M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nightingale Health
What does Nightingale Health do?
Nightingale Health provides an advanced blood analysis platform that uses proprietary NMR (Nuclear Magnetic Resonance) metabolomics technology to measure over 250 biomarkers from a single blood sample, enabling multi-disease risk prediction (cardiovascular disease, type 2 diabetes, dementia, cancer) for healthcare providers, insurers, governments, researchers, and consumers through laboratory-based and at-home service models.
Is Nightingale Health a public or private company?
Nightingale Health is a public company. It is classified as public and is currently operating.
When was Nightingale Health founded?
Nightingale Health was founded in 2013. It employs 101 to 250 people.
Where is Nightingale Health based?
Nightingale Health is headquartered in Helsinki, Finland, in the Europe region.
How does Nightingale Health make money?
Four revenue lines are on record. Healthcare Services Revenue is the primary driver. The others are consumer Health Services, research and Biobank Services and technology Licensing.
Who are Nightingale Health's main competitors?
Broad incumbents on record are Guardant Health, Bruker Corporation, Thermo Fisher Scientific, Exact Sciences and Quest Diagnostics. Metabolon is listed as a direct peer. Emerging players are GRAIL, Freenome, InsideTracker and Function Health.
Does Nightingale Health have an API?
No public API is recorded for Nightingale Health.
What industry is Nightingale Health in?
Nightingale Health's product category is Preventive Blood Diagnostics. Its primary akta.pro industry code is HLAGANAG, Metabolomics & Lipidomics Services, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 334516 and its SIC code is 3826.